[go: up one dir, main page]

EP3727362A4 - MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES - Google Patents

MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES Download PDF

Info

Publication number
EP3727362A4
EP3727362A4 EP18890811.5A EP18890811A EP3727362A4 EP 3727362 A4 EP3727362 A4 EP 3727362A4 EP 18890811 A EP18890811 A EP 18890811A EP 3727362 A4 EP3727362 A4 EP 3727362A4
Authority
EP
European Patent Office
Prior art keywords
mycophenolic acid
medicinal products
acid lipid
lipid medicinal
products
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP18890811.5A
Other languages
German (de)
French (fr)
Other versions
EP3727362A1 (en
Inventor
Daniel Kenneth BONNER
Ketki KARANAM
Sifei HAN
Luojuan HU
Christopher John Hamilton Porter
Tim QUACH
Rishab R. SHYAM
Jamie SIMPSON
Natalie TREVASKIS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Seaport Therapeutics Inc
Monash University
Original Assignee
Monash University
Puretech LYT Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Monash University, Puretech LYT Inc filed Critical Monash University
Publication of EP3727362A1 publication Critical patent/EP3727362A1/en
Publication of EP3727362A4 publication Critical patent/EP3727362A4/en
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542Carboxylic acids, e.g. a fatty acid or an amino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D307/00Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/87Benzo [c] furans; Hydrogenated benzo [c] furans
    • C07D307/88Benzo [c] furans; Hydrogenated benzo [c] furans with one oxygen atom directly attached in position 1 or 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
EP18890811.5A 2017-12-19 2018-12-19 MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES Pending EP3727362A4 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201762607749P 2017-12-19 2017-12-19
US201862724274P 2018-08-29 2018-08-29
US201862768583P 2018-11-16 2018-11-16
PCT/US2018/066585 WO2019126378A1 (en) 2017-12-19 2018-12-19 Lipid prodrugs of mycophenolic acid and uses thereof

Publications (2)

Publication Number Publication Date
EP3727362A1 EP3727362A1 (en) 2020-10-28
EP3727362A4 true EP3727362A4 (en) 2021-10-06

Family

ID=66994291

Family Applications (1)

Application Number Title Priority Date Filing Date
EP18890811.5A Pending EP3727362A4 (en) 2017-12-19 2018-12-19 MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES

Country Status (2)

Country Link
EP (1) EP3727362A4 (en)
WO (1) WO2019126378A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4306524A3 (en) 2017-08-29 2024-09-11 PureTech LYT, Inc. Lymphatic system-directing lipid prodrugs
US11883497B2 (en) 2017-08-29 2024-01-30 Puretech Lyt, Inc. Lymphatic system-directing lipid prodrugs
CN109851593B (en) * 2019-02-01 2021-04-16 沈阳药科大学 Triglyceride prodrug based on lymph-mediated transport and preparation method thereof
KR20220113737A (en) * 2019-12-06 2022-08-16 가이드 테라퓨틱스 엘엘씨 nanomaterials
EP4103542A4 (en) 2020-01-09 2024-02-14 Guide Therapeutics, LLC Nanomaterials
CN116847853A (en) 2021-01-20 2023-10-03 比姆医疗股份有限公司 Nanomaterials including biodegradable features
AU2023311822A1 (en) 2022-07-20 2025-01-09 Beam Therapeutics Inc. Nanomaterials comprising triols

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041139A1 (en) * 2015-09-08 2017-03-16 Monash University Lymph directing prodrugs
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. Lymphatic system-directing lipid prodrugs

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6013665A (en) 1997-12-16 2000-01-11 Abbott Laboratories Method for enhancing the absorption and transport of lipid soluble compounds using structured glycerides
DE60217322T2 (en) 2001-04-27 2007-10-04 Zenyaku Kogyo K.K. Heterocyclic compound and antitumor agent containing it as an active ingredient
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
DK1536827T3 (en) 2002-08-14 2009-04-20 Silence Therapeutics Ag Use of protein kinase N-beta
EA012240B1 (en) 2003-04-03 2009-08-28 Семафор Фармасьютикалз, Инк. Pi-3 kinase inhibitor prodrugs
PL1644363T3 (en) 2003-05-30 2012-07-31 Gemin X Pharmaceuticals Canada Inc Triheterocyclic compounds, compositions, and methods for treating cancer
AU2004257167B2 (en) 2003-07-03 2012-03-29 The Trustees Of The University Of Pennsylvania Inhibition of Syk kinase expression
RS55551B1 (en) 2004-05-13 2017-05-31 Icos Corp HINAZOLINONS AS HUMAN PHOSPHATIDYLINOSYTOL 3-KINASE DELTA INHIBITORS
KR101278397B1 (en) 2005-01-19 2013-06-25 리겔 파마슈티칼스, 인크. Prodrugs of 2,4-pyrimidinediamine compounds and their uses
NZ561609A (en) 2005-05-12 2010-03-26 Abbott Lab 3-((trifluoromethyl)sulfonyl)benzenesulfonamide and 3-((chloro(difluoro)methyl)sulfonyl)benzenesulfonamide apoptosis promoters
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7402325B2 (en) 2005-07-28 2008-07-22 Phoenix Biotechnology, Inc. Supercritical carbon dioxide extract of pharmacologically active components from Nerium oleander
CN103819416A (en) 2005-10-07 2014-05-28 埃克塞里艾克西斯公司 N-(3-amino-quinoxalin-2-yl)-sulfonamide derivatives and their use as phosphatidylinositol 3-kinase inhibitors
HUE028987T2 (en) 2005-11-01 2017-01-30 Targegen Inc BI-aryl-meta-pyrimidine inhibitors of kinases
EP2343298B9 (en) 2005-12-13 2020-05-06 Incyte Holdings Corporation Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي PI-3 Kinase inhibitors and methods of their use
US20090023805A1 (en) * 2006-02-13 2009-01-22 Anne Claire Marrast Method of administration
AU2007246793B2 (en) 2006-04-26 2013-02-07 F. Hoffmann-La Roche Ag Thieno [3, 2-D] pyrimidine derivative useful as PI3K inhibitor
CN101495473A (en) 2006-07-24 2009-07-29 巴斯夫欧洲公司 Azolylmethyloxiranes, use thereof for controlling plant pathogenic fungi, and agents containing the same
ES2585902T3 (en) 2006-09-22 2016-10-10 Pharmacyclics Llc Bruton tyrosine kinase inhibitors
DK2152701T3 (en) 2007-03-12 2016-02-15 Ym Biosciences Australia Pty Phenylaminopyrimidinforbindelser and uses thereof
WO2008118802A1 (en) 2007-03-23 2008-10-02 Regents Of The University Of Minnesota Therapeutic compounds
PE20090717A1 (en) 2007-05-18 2009-07-18 Smithkline Beecham Corp QUINOLINE DERIVATIVES AS PI3 KINASE INHIBITORS
KR100975520B1 (en) 2008-02-01 2010-08-12 종근당바이오 주식회사 Improved Method of Making Mycophenolate Mofetil
MY165582A (en) 2008-03-11 2018-04-05 Incyte Holdings Corp Azetidine and cyclobutane derivatives as jak inhibitors
BRPI0912326A2 (en) 2008-05-20 2015-10-06 Neurogesx Inc water soluble acetaminophen analogs
US8338439B2 (en) 2008-06-27 2012-12-25 Celgene Avilomics Research, Inc. 2,4-disubstituted pyrimidines useful as kinase inhibitors
WO2011051967A2 (en) * 2009-10-23 2011-05-05 Alkem Laboratories Ltd Pharmaceutical compositions comprising mycophenolate and processes for preparing thereof
US20110213028A1 (en) * 2010-02-26 2011-09-01 Catabasis Pharmaceuticals, Inc. Fatty acid mycophenolate derivatives and their uses
WO2016023082A1 (en) * 2014-08-12 2016-02-18 Monash University Lymph directing prodrugs

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017041139A1 (en) * 2015-09-08 2017-03-16 Monash University Lymph directing prodrugs
WO2019046491A1 (en) * 2017-08-29 2019-03-07 Ariya Therapeutics, Inc. Lymphatic system-directing lipid prodrugs
EP3675838A1 (en) * 2017-08-29 2020-07-08 Puretecch LYT, Inc. Lymphatic system-directing lipid prodrugs

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of WO2019126378A1 *

Also Published As

Publication number Publication date
EP3727362A1 (en) 2020-10-28
WO2019126378A1 (en) 2019-06-27

Similar Documents

Publication Publication Date Title
EP3727362A4 (en) MYCOPHENOLIC ACID LIPID MEDICINAL PRODUCTS AND THEIR USES
EP3478693A4 (en) BORONIC ACID DERIVATIVES AND THEIR THERAPEUTIC USES
MA53650A (en) PEG LIPIDS AND THEIR USES
MA53652A (en) HIGH PURITY PEG LIPIDS AND THEIR USES
EP3817769A4 (en) HUMAN ANTI-CD47 ANTIBODIES AND THEIR USES
EP3891183A4 (en) ANTI-CLAUDINE ANTIBODIES AND THEIR USES
EP3759143A4 (en) ANTI-TIGIT ANTIBODIES AND THEIR USES
EP3625263A4 (en) ANTI-GALECTIN-9 ANTIBODIES AND THEIR USES
EP3370770A4 (en) SUBCUTANEOUS FORMULATIONS OF ANTI-CD38 ANTIBODIES AND USES THEREOF
MA47789A (en) ANTI-PHF-TAU ANTIBODIES AND THEIR USES
EP3481430A4 (en) NUCLEIC ACID CONJUGATES AND USES THEREOF
EP3475449A4 (en) ACELLULAR NUCLEIC ACID STANDARDS AND USES THEREOF
EP3383430A4 (en) ANTIBODIES AND THEIR METHODS OF USE
MA44955A (en) ANTI-TAU BODIES AND THEIR METHODS OF USE
MA49886A (en) ANTI-PAR2 ANTIBODIES AND THEIR USES
EP2946015A4 (en) CAS9 NUCLEIC ACID COMPLEXES AND USES THEREOF
EP3518971A4 (en) THERAPEUTIC FORMULATIONS OF ANTIBODIES AND PROTEINS AND THEIR USES
EP3681912A4 (en) AXL SPECIFIC ANTIBODIES AND THEIR USES
EP3555076A4 (en) NOVEL PHENYL PROPIONIC ACID DERIVATIVES AND USES THEREOF
EP3645563A4 (en) ANTI-FAM19A5 ANTIBODIES AND THEIR USES
EP3790586A4 (en) ANTI-DLL3 ANTIBODIES AND THEIR USES
EP3672987A4 (en) ANTI-APELINE ANTIBODIES AND THEIR USES
MA44968A (en) OXABOROLE ESTERS AND THEIR USES
FR3000488B1 (en) NOVEL DERIVATIVES OF SINAPIC ACID AND THEIR COSMETIC OR PHARMACEUTICAL USES
EP3490611A4 (en) ANTIBODY CONJUGATED NANOPARTICLES AND THEIR MEDICAL USES

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20200717

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20210902

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20220614

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031138000

Ipc: A61K0045060000

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0045060000

Ipc: A61K0047540000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: C07D 307/88 20060101ALI20241009BHEP

Ipc: A61K 47/54 20170101ALI20241009BHEP

Ipc: A61K 45/06 20060101AFI20241009BHEP

RIC1 Information provided on ipc code assigned before grant

Ipc: A61P 19/02 20060101ALI20241011BHEP

Ipc: A61P 25/00 20060101ALI20241011BHEP

Ipc: A61P 1/00 20060101ALI20241011BHEP

Ipc: A61P 37/06 20060101ALI20241011BHEP

Ipc: A61P 37/00 20060101ALI20241011BHEP

Ipc: C07D 307/88 20060101ALI20241011BHEP

Ipc: A61K 45/06 20060101ALI20241011BHEP

Ipc: A61K 47/54 20170101AFI20241011BHEP

INTG Intention to grant announced

Effective date: 20241029

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONASH UNIVERSITY

Owner name: SEAPORT THERAPEUTICS, INC.

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
RAP3 Party data changed (applicant data changed or rights of an application transferred)

Owner name: MONASH UNIVERSITY

Owner name: SEAPORT THERAPEUTICS, INC.

INTG Intention to grant announced

Effective date: 20250318

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

INTC Intention to grant announced (deleted)
INTG Intention to grant announced

Effective date: 20250804

GRAJ Information related to disapproval of communication of intention to grant by the applicant or resumption of examination proceedings by the epo deleted

Free format text: ORIGINAL CODE: EPIDOSDIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

INTC Intention to grant announced (deleted)
GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED